Israeli-based biopharmaceutical firm Intec Pharma has begun a Phase I clinical trial of AP-CBD / THC for the treatment of multiple indications such as low back pain and fibromyalgia.

AP-CBD / THC is the firm's Accordion Pill platform, containing two primary cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) derived from the Cannabis sativa plant.

Used for the treatment of indications such as chronic pain, the plant's previous clinical trials provided evidence for its analgesic activity.

The single-centre, single-dose, randomised, three-way crossover Phase I trial will evaluate the pharmacokinetics, safety and tolerability of two formulations of AP-CBD / THC compared to Buccal Sativex in 21 healthy subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Sativex is a commercially available oral buccal spray made up of CBD and THC.

Intec Pharma chief executive officer Zeev Weiss said: "The progression of AP-CBD / THC into the clinic is a significant achievement for Intec and marks a major step forward in developing a potential new therapy for pain management.

"The progression of AP-CBD / THC into the clinic is a significant achievement for Intec and marks a major step forward in developing a potential new therapy for pain management."

"It is also our first demonstration of the Accordion Pill platform for cannabinoid therapies.

"Moving forward, we plan to evaluate the Accordion Pill platform in several other indications where a safe, effective, prolonged and consistent cannabinoid therapy may be able to provide therapeutic benefit where other treatments have failed."

AP-CBD / THC is reported to possess the potential to address major drawbacks such as short-effect duration, delayed onset, variability of exposure and the administered dose, and adverse events of the existing treatments.

It is expected that the top-line results from the trial will be reported in the third quarter of this year.

Image: THC-filled trichomes on a Cannabis sativa leaf. Photo: courtesy of Indirectantagonist/Wikipedia.